A Phase 4 interventional study of Oral Vancomycin in Clostridium Difficile Infection, sponsored by University of Nevada, Reno. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-28.
Sponsored by University of Nevada, Reno · Phase 4, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing vancomycin in Clostridium Infections — 4 open to participants now, 4 under way, 2 of them phase 3. Vancomycin · Clostridium Infections.
Among the 20 studies testing vancomycin in Clostridium Infections, this one is the 7th largest by enrollment, is one of 3 that started in 2018, is one of 10 in phase 4, and was the 10th registered.
251 studies on the registry are indexed under Clostridium Infections; 51 are open to participants now.
Browse Clostridium Infections studies →4 of the 20 studies testing vancomycin in Clostridium Infections are open now, in 2 countries. Recruiting first, the newest first:
Riverside University Health System Medical Center · Sites in United States
Ages 18+
Leiden University Medical Center · Sites in Netherlands
Ages 18–45 · Healthy volunteers
Brigham and Women's Hospital · Sites in United States
Ages 18+
Assistance Publique - Hôpitaux de Paris
Ages 15+
By country, each count listing its studies:
Vancomycin: first FDA approval 1964 (VANCOCIN HYDROCHLORIDE). What it is approved for, and how studies give it, is on its page →
Of the 36 Clostridium Infections studies recruiting now, 22 (61%) set no upper age limit and 8 (22%) stop at 75 or younger; 9 take children under 18; 3 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 5 · Phase 3 5 · Phase 4 10
First in 2012; this study’s year is marked. 3 started in 2018.
This study's enrollment of 104 is above the median of 64 across 185 interventional studies indexed under Clostridium Infections.
Median enrollment 63 across the 20 interventional studies. Of the 14 that completed or were terminated, 8 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 20 has an industry lead sponsor. The 10 most frequent:
University of Nevada, Reno is the lead sponsor of 28 studies on the registry; 5 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.
University of Nevada, Reno has 1 study filed under Clostridium Infections — fewer than ten, so there is no comparison to draw.
1 of the studies testing vancomycin in Clostridium Infections that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07221370Phase 3Riverside University Health System Medical CenterEnteral Vancomycin as Primary Prophylaxis Against Clostridioides Difficile Infection in Critically Ill Patients | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 20 studies testing vancomycin in Clostridium Infections, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will assess the efficacy of oral vancomycin prophylaxis in preventing recurrent Clostridium difficile infection in hospitalized patients requiring oral or intravenous antibiotics for a suspected or confirmed bacterial infection.
This study will assess the efficacy of oral vancomycin prophylaxis in preventing recurrent Clostridium difficile infection in hospitalized patients requiring oral or intravenous antibiotics for a suspected or confirmed bacterial infection.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: Oral Vancomycin
Drug: Oral Vancomycin
Oral vancomycin will be given concurrently with antibiotics to hospitalized patients with a history of Clostridium difficile infection to prevent recurrence
Recurrent Clostridium difficile infection
Diarrheal illness, with at least 3 episodes of watery diarrhea over a 24 hour period and a positive toxin analysis or a positive PCR for Cdiff
Time frame: During hospitalization or the 12 weeks after therapy
Recurrence rate of CDI according to C diff inducing properties of the prescribed antibiotics
* Low inducers: aminoglycosides, fosfomycin, glycopeptides, daptomycin, nitrofurantoin, linezolid, polymyxins, rifamycins, antifolates and/or sulfonamides, tetracyclines, tigecycline * Moderate inducers: penicillins, 1st generation cephalosporins, macrolides, azithromycin, streptogramins * High inducers: carbapenems, 2nd and greater generation cephalosporins, fluoroquinolones, clindamycin
Time frame: During hospitalization or the 12 weeks after therapy
Time between recurrent CDI and the last C diff infection
Time frame: During hospitalization or the 12 weeks after therapy
Rate of recurrence of CDI in immunocompromised patients
HIV, Organ Transplantation, Current Immunosuppressive therapy, Hypogammaglobulinemia or steroids dose more than prednisone 20mg/day for 3 weeks
Time frame: During hospitalization or the 12 weeks after therapy
Rate of recurrence of CDI in patients with a history of the NAP-1 strain
Time frame: During hospitalization or the 12 weeks after therapy
Rate of reported adverse events
Time frame: During hospitalization or the 12 weeks after therapy
Mortality rate
Time frame: During hospitalization or the 12 weeks after therapy
Plan to share: No
No publications or documents are linked to this record.
Ran from Mar 2018 to primary completion in Feb 2022, 47 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vancomycin
University of Nevada, Reno